Niosomal daunorubicin with reduced toxicity and improved anticancer activity in Swiss mice bearing fibrosarcoma

Agrawal Sunil, R. D'Souza, N. Udupa, K. Guruprasad, P. Uma Devi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Non-ionic surfactant vesicles (niosomes) are promising drug carriers for anticancer drugs. With the aim to modify drug disposition and to increase the therapeutic efficacy of the drug, daunorubicin, niosomes were prepared by dichloromethane injection method. The preparations were then characterized with respect to size and its distribution, entrapment efficiency, in vitro drug release profile and its stability under specified conditions. Anti-tumor efficacy bearing solid tumour (fibrosarcoma) and organ toxicity studies in Swiss mice were conducted with the niosomes administered by intravenous route at a dose of 5 & 10 mg kg-1 body weight. Niosomes were spherical, though occasionally oval with a mean diameter of 4.6 μm. The entrapment efficiency of the drug was found to be 93.97 ± 1.71%, with the drug being incorporated into the aqueous layer of the vesicles. Prepared niosomes were stable as evident by less drug leakage under different conditions of storage and released the loaded drug in a controlled fashion. Anti-tumor studies indicate a significant difference (P<0.05) in volume doubling time between the free drug and daunorubicin niosomes at both doses. The animals treated with drug formulation also exhibited dramatic decrease in cardiac toxicity. The results revealed that encapsulation of daunorubicin in niosomes is a potential tool for the effective delivery of drug, as this formulation not only reduces the cardiotoxicity associated with it but also enhances antitumour efficacy.

Original languageEnglish
Pages (from-to)21-26
Number of pages6
JournalIndian Drugs
Volume38
Issue number1
Publication statusPublished - 01-2001

Fingerprint

Daunorubicin
Fibrosarcoma
Liposomes
Pharmaceutical Preparations
Drug Compounding
Neoplasms
Drug Carriers
Methylene Chloride
Surface-Active Agents
Body Weight
Injections

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Sunil, Agrawal ; D'Souza, R. ; Udupa, N. ; Guruprasad, K. ; Uma Devi, P. / Niosomal daunorubicin with reduced toxicity and improved anticancer activity in Swiss mice bearing fibrosarcoma. In: Indian Drugs. 2001 ; Vol. 38, No. 1. pp. 21-26.
@article{0df286bcdfa4494eb7196de50a230044,
title = "Niosomal daunorubicin with reduced toxicity and improved anticancer activity in Swiss mice bearing fibrosarcoma",
abstract = "Non-ionic surfactant vesicles (niosomes) are promising drug carriers for anticancer drugs. With the aim to modify drug disposition and to increase the therapeutic efficacy of the drug, daunorubicin, niosomes were prepared by dichloromethane injection method. The preparations were then characterized with respect to size and its distribution, entrapment efficiency, in vitro drug release profile and its stability under specified conditions. Anti-tumor efficacy bearing solid tumour (fibrosarcoma) and organ toxicity studies in Swiss mice were conducted with the niosomes administered by intravenous route at a dose of 5 & 10 mg kg-1 body weight. Niosomes were spherical, though occasionally oval with a mean diameter of 4.6 μm. The entrapment efficiency of the drug was found to be 93.97 ± 1.71{\%}, with the drug being incorporated into the aqueous layer of the vesicles. Prepared niosomes were stable as evident by less drug leakage under different conditions of storage and released the loaded drug in a controlled fashion. Anti-tumor studies indicate a significant difference (P<0.05) in volume doubling time between the free drug and daunorubicin niosomes at both doses. The animals treated with drug formulation also exhibited dramatic decrease in cardiac toxicity. The results revealed that encapsulation of daunorubicin in niosomes is a potential tool for the effective delivery of drug, as this formulation not only reduces the cardiotoxicity associated with it but also enhances antitumour efficacy.",
author = "Agrawal Sunil and R. D'Souza and N. Udupa and K. Guruprasad and {Uma Devi}, P.",
year = "2001",
month = "1",
language = "English",
volume = "38",
pages = "21--26",
journal = "Indian Drugs",
issn = "0019-462X",
publisher = "Indian Drug Manufacturers' Association",
number = "1",

}

Niosomal daunorubicin with reduced toxicity and improved anticancer activity in Swiss mice bearing fibrosarcoma. / Sunil, Agrawal; D'Souza, R.; Udupa, N.; Guruprasad, K.; Uma Devi, P.

In: Indian Drugs, Vol. 38, No. 1, 01.2001, p. 21-26.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Niosomal daunorubicin with reduced toxicity and improved anticancer activity in Swiss mice bearing fibrosarcoma

AU - Sunil, Agrawal

AU - D'Souza, R.

AU - Udupa, N.

AU - Guruprasad, K.

AU - Uma Devi, P.

PY - 2001/1

Y1 - 2001/1

N2 - Non-ionic surfactant vesicles (niosomes) are promising drug carriers for anticancer drugs. With the aim to modify drug disposition and to increase the therapeutic efficacy of the drug, daunorubicin, niosomes were prepared by dichloromethane injection method. The preparations were then characterized with respect to size and its distribution, entrapment efficiency, in vitro drug release profile and its stability under specified conditions. Anti-tumor efficacy bearing solid tumour (fibrosarcoma) and organ toxicity studies in Swiss mice were conducted with the niosomes administered by intravenous route at a dose of 5 & 10 mg kg-1 body weight. Niosomes were spherical, though occasionally oval with a mean diameter of 4.6 μm. The entrapment efficiency of the drug was found to be 93.97 ± 1.71%, with the drug being incorporated into the aqueous layer of the vesicles. Prepared niosomes were stable as evident by less drug leakage under different conditions of storage and released the loaded drug in a controlled fashion. Anti-tumor studies indicate a significant difference (P<0.05) in volume doubling time between the free drug and daunorubicin niosomes at both doses. The animals treated with drug formulation also exhibited dramatic decrease in cardiac toxicity. The results revealed that encapsulation of daunorubicin in niosomes is a potential tool for the effective delivery of drug, as this formulation not only reduces the cardiotoxicity associated with it but also enhances antitumour efficacy.

AB - Non-ionic surfactant vesicles (niosomes) are promising drug carriers for anticancer drugs. With the aim to modify drug disposition and to increase the therapeutic efficacy of the drug, daunorubicin, niosomes were prepared by dichloromethane injection method. The preparations were then characterized with respect to size and its distribution, entrapment efficiency, in vitro drug release profile and its stability under specified conditions. Anti-tumor efficacy bearing solid tumour (fibrosarcoma) and organ toxicity studies in Swiss mice were conducted with the niosomes administered by intravenous route at a dose of 5 & 10 mg kg-1 body weight. Niosomes were spherical, though occasionally oval with a mean diameter of 4.6 μm. The entrapment efficiency of the drug was found to be 93.97 ± 1.71%, with the drug being incorporated into the aqueous layer of the vesicles. Prepared niosomes were stable as evident by less drug leakage under different conditions of storage and released the loaded drug in a controlled fashion. Anti-tumor studies indicate a significant difference (P<0.05) in volume doubling time between the free drug and daunorubicin niosomes at both doses. The animals treated with drug formulation also exhibited dramatic decrease in cardiac toxicity. The results revealed that encapsulation of daunorubicin in niosomes is a potential tool for the effective delivery of drug, as this formulation not only reduces the cardiotoxicity associated with it but also enhances antitumour efficacy.

UR - http://www.scopus.com/inward/record.url?scp=6644228815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6644228815&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:6644228815

VL - 38

SP - 21

EP - 26

JO - Indian Drugs

JF - Indian Drugs

SN - 0019-462X

IS - 1

ER -